Astellas Pharma gets grant for novel carbocyclic prolinamide derivatives for treating age-related macular degeneration

Discover Astellas Pharma's patented carbocyclic prolinamide derivatives for treating eye diseases like macular degeneration. Explore the unique compound structure and potential applications in pharmaceuticals and beyond.

Related Posts

Alvotech and Polifarma sign agreement to commercialise ...

May 10, 2023

Biden’s administration initiative aims to advance women...

Mar 20, 2024

FDA clears PK Med to streamline gout injectable to Phas...

Feb 26, 2024